Strong topline, margin compression, pipeline-rich transformation story
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Met headline growth (44.9% YoY), but margin compression (QoQ PAT -6.4%) and tax benefit (₹28 Cr) mask underlying pressure. Declined forward guidance; prior call suggested 'product launches and capacity expansions from FY27.' On track, but less committal now.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong structural transformation (net debt 6.7x→1.3x, ROCE 8.8%→12.5%, AA- rating) and multi-year pipeline (Biologics, CDMO, complex formulations) support thesis. But Q1 reveals near-term headwinds: QoQ PAT -6.4% despite revenue growth (margin compression), ₹28 Cr one-time tax benefit masking operational weakness, Nor-UDCA domestic softness, gross margin down from FX/commodities. High capex (₹114 Cr/Q) constrains near-term FCF. Pipeline execution (FY27-28 launches, CDMO ramp) is critical; any delay would reset growth trajectory. Rating: Hold pending next 2 quarters to confirm margin stabilization and pipeline monetization.
₹465.8 Cr
Revenue · +44.9% YoY₹100.9 Cr
Reported PAT · +115.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Record quarter driven by every part of business
METRevenue ₹466 Cr (+45% YoY). All segments contributed: Formulation +112%, API +15%, Biologics +42%. But QoQ revenue +6.6%, PAT -6.4%, indicating margin deterioration.
Nor-UDCA performing as expected, strong order visibility
OVERSTATEDDomestic Formulation revenue dipped QoQ despite product launched Q3 FY26. Management refuses product-level disclosure, deflects to 'stocking variation.' Analyst skepticism evident on 6-month ramp trajectory.
Operating leverage and margin expansion ahead
OVERSTATEDEBITDA margin 30%, EBITDA PAT 21.5% (vs. 29.3% OPM delivered). Gross margin 71%, down YoY due to raw material inflation. QoQ margin compressed despite 6.6% revenue growth.
Reinvesting largely behind us, harvesting ahead
OVERSTATEDCapex ₹114 Cr/Q (₹456 Cr annualized, ~98% of Q1 revenue). Self-funded via internal accruals, but remains heavy. Not 'largely behind.'
Three 505(b)(2) formulations performing well, sales growing QoQ
METIncluded in Formulation +112% growth. Individual product metrics not disclosed; cannot independently verify trajectory or sustainability.
Earnings quality
What changed since the last call
Guidance withdrawn to vague language
WithdrawnPrior call: 'Product launches and capacity expansions from FY27 onwards.' This call: 'Healthy steady growth, faster profitability.' No numeric targets provided; more cautious tone.
CDMO milestone timing confirmed
Upgrade3 late-stage programs now visible to enter commercialization FY28. Improves confidence on near-term revenue inflection vs. prior vague 'multiple programs' language.
Margin outlook hedged
DowngradeNo expansion guidance given. Management emphasizes 'conservative and overdeliver,' expects range ~30% EBITDA. Gross margin headwinds (FX, raw materials) being managed, not overcome.
Capex commitment reaffirmed at high level
Neutral₹114 Cr/Q capex for Biologics, Albumin, API completion. 'Self-funded' but represents ~₹450 Cr annually. Consistent with transformation narrative but high burn rate.
The Q&A
Analysts pressed hard on specifics: Nor-UDCA domestic dip (deflected to stocking variation), gross margin sustainability (admitted FX/commodity headwinds, partial customer pass-through), CDMO scale ambitions (declined to quantify target vs. peer ₹800-1000 Cr benchmarks), capex deployment rationale (won't segment by division). Management held firm on non-disclosure but provided coherent strategy narrative. Skepticism audible on Nor-UDCA trajectory and margin defensibility in current environment.
Capex vs. asset utilization — Sajal Kapoor, Antifragile Thinking
AnsweredBiologics and Formulations have low utilization, room for growth. API high-utilization justifies incremental capex. Mix of both keeps capital deployed for growth.
Growth and risk guidance — Gaurav Bhardwaj, Techsecfunda Investment Advisors
PartialCannot provide specific guidance. Expect healthy steady growth from Biologics and niche Formulations monetization. Main barrier: regulatory pathway risk.
Nor-UDCA sales breakdown — Krisha Kansara, Molecule Ventures
DodgedDo not disclose product-level numbers. Strong order trajectory. Clinical data published online; Phase IV ongoing.
Biologics team scaling — Krisha Kansara, Molecule Ventures
DodgedOperational question, can discuss offline. Strong mixed team with consultants on US/EU regulations. No specific roadmap disclosed.
API division growth drivers — Yash Doshi, Unifi Capital
AnsweredInnovative CDMO.
Japanese customer on-boarding — Yash Doshi, Unifi Capital
DodgedConfidentiality on program; will share details in upcoming call.
Nor-UDCA QoQ dip — Yash Doshi, Unifi Capital
PartialNot a product-level detail. Stocking and manufacturing schedules vary quarter-to-quarter. Product overall doing well.
CDMO scale benchmarking — Tushar Bohra, MK Ventures
PartialSizable business. Won't disclose target. Have 25+ NCE programs, 1 commercial today. Growth will depend on program advancement.
CDMO program ramp timing — Tushar Bohra, MK Ventures
AnsweredDepends on partner. Visibility next year: 3 NCE programs entering commercial phase.
CDMO financial upside — Tushar Bohra, MK Ventures
AnsweredYes, you are right.
Gross margin drivers and sustainability — Sumit Gupta, Antique Stock Broking
PartialComplex products (Rotigotine, Abraxane, NCEs, 505b2s) drive margins. Raw material inflation (global politics) pressure; partial pass-through to customers.
Gross margin normalization — Sumit Gupta, Antique Stock Broking
PartialDifficult to quantify; pass-through to customer varies. Timing difference based on contract positioning.
Tax regime switch rationale — Nishant, Grodun
AnsweredR&D units fully built; no significant future R&D capex expected. Effective tax rate benefit (~10%) outweighs lost depreciation. Leveraging MAT credit.
US tariff impact — Nishant, Grodun
AnsweredNot selling me-too generics to US; all complex products. Monitoring Trump administration stance. No immediate US facility plan.
Europe revenue decline — Akhilesh Pathak, Smart Sync Services
PartialTendered products; quarter-to-quarter supply variation normal. No structural dip; product and market performing well.
Plant capacity utilization — Akhilesh Pathak, Smart Sync Services
DodgedConnect with Monish (IR Head) for segmental utilization details.
Biologics ROCE and asset trajectory — Amish Kanani, Knowise Investment Managers
PartialBiologics: 8 biosimilars not yet partnered (vs. 1 Nivolumab in Europe). Albumin: Phase I done, starting Phase III globally, already partnered in Europe. Potential significant. Won't quantify segment-wise ROCE.
Licensing income economics — Ajay, Niveshaay
PartialCannot segregate numbers. Licensing fees significantly higher than R&D spend. Project-dependent, non-recurring. Mixed with continuous development cycles.
Licensing income recurring vs. lumpy — Ajay, Niveshaay
AnsweredB2B model: we develop products and license out. No in-market presence. More portfolio development = more licensing opportunity.
CDMO business customers — Tirumala Reddy, Individual Investor
Answered20+ CDMO customers across Shilpa Group.
Adalimumab commercial outlook — Tirumala Reddy, Individual Investor
AnsweredDoing well in India via partner with strong arthritis reach. Not a big opportunity; first product to prove capability. Moving to complex products (Aflibercept, Nivolumab).
505(b)(2) ramp trajectory — Yash Doshi, Unifi Capital
PartialDo not disclose product-level numbers. Complexity and differentiation vs. generics key to sustainability. Good long-term opportunity.
Complex FDA products launch type — Yash Doshi, Unifi Capital
AnsweredMix. Rotigotine: first-wave generic. Abraxane: second-wave (few players but complex, tender-featured). Select only products with sustainable long-term growth.
Oncology API and Formulation integration — Ajay, Niveshaay
AnsweredOncology API growth depends on end-customer adoption and molecules commoditizing timeline. Visibility on end-customer interest already. Formulation: 50%+ captive from internal APIs.
Biologics strategy shift — Ajay, Niveshaay
AnsweredMixed strategy. Short-to-mid term: biosimilars and CDMO. Long term: strategic partnerships (Alveolus, mAbTree) for longer-term bets with significant upside.
Orion partnership timeline — Ajay, Niveshaay
DodgedNo client/product-specific disclosure. Connect with Monish for whatever details possible.
Guidance
No explicit FY27 revenue target provided
LowManagement says 'healthy and steady growth' from pipeline launches (Formulation FY27-28, CDMO FY28). Implies low-to-mid 20s growth, but unquantified.
EBITDA margins to 'remain in similar range' (~30% level)
MediumAcknowledges raw material headwinds. Says 'conservative and overdeliver' approach; won't commit to expansion.
Gross margin will benefit from complex product launches (Rotigotine, Abraxane, NCEs, 505b2s)
MediumBut admits FX/commodity pressure ongoing. Partial pass-through to customers. Sustainability depends on normalization.
₹114 Cr/Q (~₹456 Cr annualized) to complete Biologics, Albumin, API investments
HighSays 'no significant capex for next 3 years' in Biologics/Albumin post-FY27. API and select Formulation capex to continue.
Risks the call surfaced
Pipeline execution
HighFormulation launches (Rotigotine FY28, Abraxane/Enzalutamide/Abiraterone FY28) and Biologics launches (Aflibercept FY27, Nivolumab FY28) core to growth thesis. Any delay would materially impact near-term revenue and margin recovery.
Margin sustainability
MediumGross margin 71%, down from 75%+ due to raw material inflation (political disruptions) and FX headwinds. QoQ PAT -6.4% despite revenue +6.6% signals cost pressure overcoming volume gains. If headwinds persist, EBITDA margin could compress below 30%.
Nor-UDCA market adoption
MediumNor-UDCA, positioned as NCE growth driver, showed domestic revenue dip QoQ despite 6-month post-launch. Management claims stocking variation, but analyst skepticism evident. Emcure's semaglutide approval for NAFLD could limit Nor-UDCA opportunity. Global Phase II just starting FY27; commercialization 2+ years away.
CDMO program dependency
MediumCDMO business has 20+ customers but only 1 commercial product. Revenue dependent on partner execution (programs run by partner, not Shilpa). Most programs Phase I-II, 2-5 years to commercialization. Loss of key partner or major program delay would impact near-term revenue.
Regulatory and compliance
MediumComplex formulations and biologics subject to evolving regulatory standards. Any manufacturing issue or product safety event could delay launches or trigger recalls. U.S. tariff threat (₹45 Cr exports, ~10% of revenue) on generic drugs, though management downplays impact on complex products.
Management
Score 7/10. Clear and detailed on strategy (CDMO, Biologics, Formulation pipeline). Articulate on transformation metrics (debt 6.7x→1.3x, ROCE 8.8%→12.5%). But evasive on product-level numbers (Nor-UDCA sales, formulation margins) and won't quantify targets (CDMO scale vs. peers, Biologics runway). Transparency moderate. Track record mixed. Topline growth delivered (44.9% YoY). Transformation metrics (debt, ROCE, rating upgrade) on track. But margin compression (QoQ PAT -6.4%), Nor-UDCA domestic softness, and tax benefit inflation signal execution gaps. Pipeline launches on track, but most major catalysts 1-2+ years away.
1 · Q2-Q3 FY27
Rotigotine US launch, Aflibercept India market entry, Nor-UDCA Phase II global initiation
2 · Q4 FY27 / Q1 FY28
3 CDMO programs enter commercialization; Nivolumab India clinical study progress
3 · FY28
Abraxane, Enzalutamide, Abiraterone formulation launches; Albumin Phase III global trial ongoing
Rating: Hold pending next 2 quarters to confirm margin stabilization and pipeline monetization.
The ₹28 Crore Mask: Transformation Real, Execution Risky
Reported PAT surged 115%, but ₹28 crore one-time tax benefit masks a deteriorating margin picture. QoQ profit fell despite 6.6% revenue growth—a warning that near-term headwinds (FX, raw materials, Nor-UDCA softness) are overwhelming volume gains.
₹101 Cr
+115% YoY
₹28 Cr
Regime switch
~₹73 Cr
+60% YoY
-6.4%
Despite revenue +6.6%
The ₹28 crore that distorts the quarter
Shilpa Medicare's reported PAT of ₹101 crore in Q1 FY27 tells a headline story: +115% YoY, a blowout. But ₹28 crore of that gain is a one-time tax benefit from switching to India's new corporate tax regime. Strip that out, and adjusted PAT lands at roughly ₹73 crore—a solid +60% YoY, but fundamentally different from the reported print. The tax benefit alone accounts for 28% of headline profit.
R&D units are fully built now. We don't have significant future R&D capex expected. The effective tax rate benefit outweighs the lost depreciation. We're leveraging the MAT credit.
The margin squeeze: QoQ PAT fell despite revenue growth
Here's the red flag that undercuts management's "operating leverage" narrative: revenue grew 6.6% quarter-on-quarter, but PAT fell 6.4%. This inconsistency—volume up, profit down—reveals that cost and FX headwinds are overwhelming topline gains. Gross margin compressed to 71% from prior highs of 75%+, driven by raw material inflation (blamed on geopolitical disruption) and FX volatility. QoQ, the company saw partial customer pass-through of cost increases, suggesting pricing power is limited in the near term.
Record quarter driven by every part of business
Revenue ₹466 Cr (+45% YoY). All segments contributed: Formulation +112%, API +15%, Biologics +42%. But QoQ revenue +6.6%, PAT -6.4%, indicating margin deterioration.
Supported (headline), but with caveat
Nor-UDCA performing as expected, strong order visibility
Domestic Formulation revenue dipped QoQ despite product launched Q3 FY26. Management deflects to 'stocking variation.' Analyst skepticism evident on 6-month ramp trajectory.
Overstated
Operating leverage and margin expansion ahead
QoQ PAT -6.4% despite +6.6% revenue growth. EBITDA margin 30%, no expansion guidance given. Gross margin down YoY.
Overstated
Reinvesting largely behind us, harvesting ahead
Capex ₹114 Cr/Q (~₹456 Cr annualized, ~98% of Q1 revenue). Self-funded but remains heavy. Not 'largely behind.'
Overstated
What shifted on this call
Three key moves from management: 1. Guidance withdrawn to vague language. Prior calls suggested 'product launches and capacity expansions from FY27 onwards.' This quarter: 'healthy and steady growth' with no numeric targets. The tone is more cautious, and analysts pressed hard—without success—for specifics on CDMO scale targets, Biologics revenue runways, and Nor-UDCA domestic trajectory. 2. CDMO milestones confirmed. Management clarified that 3 late-stage programs are now visible to enter commercialization in FY28, a refinement of prior vague 'multiple programs' language. This is positive—concrete catalysts. But timeline risk remains high (programs run by partners, not Shilpa). 3. Capex reaffirmed at high level. ₹114 Cr/quarter for Biologics, Albumin, and API completion. Management says this is 'self-funded' and 'largely behind us' post-FY27, but the run-rate remains intense: ~₹456 Cr annualized, or 98% of Q1 revenue. FCF will be constrained near-term.
Earnings quality flags
Tax benefit ₹28 Cr inflated PAT by 28%; normalized growth ~60%, not 115%
QoQ PAT declined despite 6.6% QoQ revenue growth—margin pressure is real
Gross margin 71%, down from 75%+; FX/commodity headwinds admitted, not solved
Formulation +112% includes lumpy licensing income; ex-licensing, base growth ~102%
Nor-UDCA domestic dip QoQ despite 6-month post-launch; management deflects to stocking
The transformation thesis—real, but risky
Strip away the near-term noise and Shilpa's structural story is genuinely strong. Net debt improved from 6.7x EBITDA to 1.3x in three years; ROCE climbed from 8.8% to 12.5% (18.3% adjusted ex-Biologics). Credit rating upgraded to AA-. The company has built a rare integrated platform: small molecules + large molecules + APIs + complex generics + CDMO all under one roof. No peer India-based CDMO has this mix. But the quarter reveals a timing risk. Management is banking on FY27–28 pipeline launches (Rotigotine, Abraxane, Aflibercept, Nivolumab, CDMO programs) to drive the next leg of growth and margin recovery. Any delay—regulatory setback, clinical hold, manufacturing ramp issue—would reset the thesis. The capex burn (₹456 Cr annualized) is being justified on these catalysts. If they slip, FCF suffers and the debt story stalls.
How the street is positioned
The market verdict on the result is mixed. On day 1 post-announcement, the stock popped 2.4%, but then rallied hard: day 3 saw +11.9%, day 5 +11.6%, lifting the stock above its 52-week SMA20, SMA50, and SMA200. At ₹822 (as of Aug 14), it sits just 0.41% below its all-time high, having climbed 217% off the 52-week low. Technical momentum is very strong. But the technicals mask caution underneath. RSI at 87.9 signals overbought conditions—typically a warning signal. Ownership flows show FII buying (+0.3pp to 11.4% Q1) while DII trimmed (-0.53pp to 8.1%). Bulk trading by Microcurves around the result date (buying at ₹723, then selling at ₹760) suggests arb/rebalance activity rather than conviction from anchored capital. The price action suggests the street is pricing the transformation thesis and the pipeline catalysts—the right fundamental call. But valuation at all-time high with overbought technicals leaves little room for near-term stumbles. If Nor-UDCA adoption remains soft, or pipeline launches slip into FY29, or margin pressure persists into Q2–Q3, the stock could face a sharp reset.
Risks, ranked by severity
Margin compression persists; QoQ PAT decline is a trend, not a blip
HighIf FX/commodity headwinds extend into Q2–Q3 and customer pricing power remains limited, EBITDA margin could fall below 30%. This would reset both the profitability thesis and debt serviceability story.
Nor-UDCA domestic adoption slower than guided; product peaks at current level
HighPositioned as a domestic growth driver, but shows QoQ dip 6 months post-launch. If this is a trend, not stocking variation, then FY27 revenue growth underperforms expectations.
Pipeline launch delays: regulatory setback, manufacturing ramp, partner delays
HighRotigotine, Abraxane, CDMO programs, Aflibercept, Nivolumab are the 2-year thesis. Any slippage into FY28–29 would soften near-term topline and reset margin recovery timeline.
CDMO program loss or major partner setback
MediumCDMO has 20+ customers and 25+ programs, but only 1 commercial product. Most programs Phase I–II, 2–5 years to commercialization. Partner loss or program failure would impact revenue.
Capex execution slips; ROI on ₹456 Cr annual investment delayed
MediumHeavy capex justified on pipeline catalysts. If Biologics/Albumin/API buildouts slip or returns disappoint, FCF stalls and debt reduction slows.
What to watch next
1 · Gross margin stabilization (Q2–Q3)
Track whether FX/commodity headwinds ease and customer pass-through accelerates. If gross margin bounces back above 72%, the margin compression narrative weakens. If it stays flat or declines further, the structural story breaks.
2 · Nor-UDCA domestic ramp: QoQ or YoY growth trajectory
Management claims 'strong order visibility' but the data shows a dip. Next 2 quarters will reveal whether Q1 was a one-off stocking issue or the start of slower adoption. This is a credibility test for management.
3 · First CDMO commercialization milestone; Rotigotine US launch status
These are the catalysts that justify capex and resolve the pipeline execution risk. Confirmation that the 3 late-stage CDMO programs are advancing on schedule (not delayed) and Rotigotine is on track for FY28 US entry would support the bull thesis.
The honest read
Shilpa Medicare delivered headline topline growth (+45% YoY) and a transformed balance sheet (debt 6.7x→1.3x, ROCE 8.8%→12.5%). But this quarter is not a step-change. Reported PAT leans on a ₹28 Cr one-time tax benefit; adjusted profit growth is solid (+60%), not explosive. More concerning: QoQ PAT fell despite revenue growth, signaling that margin headwinds (FX, raw materials) are real and near-term.
The transformation thesis—moving from a commodity generics player to an integrated CDMO and complex-pharma platform—is real and offers structural upside. But the timing of realized value is now 1–2+ years out, riding on pipeline execution (Rotigotine, Abraxane, CDMO programs, Biologics launches in FY27–28). Management has withdrawn numeric guidance, likely because near-term visibility is limited and near-term headwinds are material.
The stock is overbought on technicals and priced at all-time high. This quarter is a Hold: the transformation story supports long-term ownership, but near-term execution risk (margin, Nor-UDCA ramp, pipeline timing) argues for caution. The number to track from here is the adjusted PAT (ex-one-time items). If adjusted profit growth stalls or margins compress further in Q2–Q3, the bull thesis weakens materially. If margins stabilize and CDMO/Biologics catalysts confirm, the dip is a buying opportunity.
Shilpa Medicare Q1 FY27: PAT ₹101 Cr, +115% YoY but adjusted growth ~61% ex tax boost
PAT +115.16% YoY · revenue +44.9% · margins expanding
₹465.78 Cr
+44.9% YoY
₹100.88 Cr
+115.16% YoY
21.51%
+7.2pp YoY
₹5.16
On a consolidated basis (primary), Shilpa Medicare's Q1 FY27 revenue rose 44.9% YoY to ₹465.78 Cr (₹321.46 Cr a year ago) and 6.6% QoQ (₹436.99 Cr in Q4 FY26). Reported PAT more than doubled YoY to ₹100.88 Cr (+115.2%) but eased 6.4% QoQ from ₹107.79 Cr. The YoY PAT jump is not a clean operating story: tax expense flipped to a net credit of ₹2.83 Cr this quarter (from ₹269 lakhs YoY) after a one-time deferred-tax liability reversal of roughly ₹25.36 Cr, booked after the company remeasured deferred tax balances under the new income-tax regime (Section 200, Income-tax Act 2025). Stripping that reversal out, adjusted PAT is closer to ₹75.5 Cr, putting adjusted YoY PAT growth at roughly +61% — still strong and ahead of revenue growth, but well short of the 115% headline.
Q1 FY-2027 vs prior quarters
Margins tell a similar story: reported consolidated NPM expanded to 21.7% from 14.3% a year ago (24.6% in Q4 FY26), but on an adjusted basis NPM is closer to 16.2% — a smaller but genuine YoY gain, and a step down from an adjusted ~18.9% in Q4 FY26 (which itself carried a ₹25.02 Cr exceptional gain). The underlying expense ratio did improve — total expenses fell to 80.4% of total income from 84.7% a year ago — consistent with operating leverage as revenue scaled, and consolidated PBT also got a modest lift from JV/associate income swinging to +₹5.96 Cr from -₹0.73 Cr a year ago. Standalone PAT of ₹64.92 Cr (+247% YoY) grew far faster than consolidated, but that divergence is largely a base effect: standalone Q1 FY26 carried a ₹5.18 Cr exceptional loss while this quarter carries a ₹3.51 Cr exceptional gain, in addition to the same tax reversal — the two bases are not comparable without adjustment.
The stock went into the print at ₹653.65, up 9% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management expresses strong confidence in future growth driven by a differentiated pharmaceutical platform spanning complex APIs, specialty formulations, biologics, and ADCs with integrated CDMO capabilities. They anticipate sustainable growth, stronger margins, and increased return ratios in the coming years, with spe
— This quarter: met
Management issued no separate press release with this filing (none available at the time of this analysis), and no formal quantitative guidance exists on record — the only prior signal is the Q4 FY26 concall's qualitative confidence in FY27 growth from complex APIs, specialty formulations, biologics, ADCs and CDMO capacity, without numbers attached. This quarter's revenue and adjusted-PAT growth are directionally consistent with that framing, and it coincided with the commissioning of an integrated ADC GMP manufacturing facility at Shilpa Biologicals (June 24) and a Nivolumab biosimilar partnership with Orion Corp (June 30) — both consistent with the CDMO/biologics build-out management flagged. Leadership churn at the Biologicals subsidiary continued in parallel: its CEO resigned for personal reasons on July 15 and a replacement was appointed August 3, alongside a ₹9 Cr legal-settlement disclosure at the same subsidiary on June 24. No Q1 FY27-specific street estimate could be located; the only consensus figure found was an annual FY27 EPS estimate of ~₹13.75, not comparable to a single quarter.
W1
Whether the ~₹25 Cr one-time deferred-tax reversal was a one-quarter event — check if Q2 FY27's effective tax rate normalizes toward a more typical level versus this quarter's net tax credit on ₹98.06 Cr consolidated PBT.
W2
Whether adjusted PAT growth (~61% YoY this quarter) sustains as the newly commissioned ADC GMP facility and the Orion Corp Nivolumab biosimilar partnership start contributing to revenue.
W3
Consolidated PAT eased 6.4% QoQ (reported) from Q4 FY26's ₹107.79 Cr — watch whether Q2 FY27 resumes sequential growth or this proves a base/seasonal effect.
Both statements are clean, legible, unaudited (limited-review, unmodified opinion). Standalone had a ₹3.51 Cr exceptional income (ECL reversal on foreign-subsidiary loans); consolidated had nil exceptional items this quarter vs a ₹25.02 Cr exceptional gain in Q4 FY26. A one-time deferred-tax liability reversal (new income-tax regime remeasurement, note 7) added ~₹26.84 Cr (standalone) / ~₹25.36 Cr (consolidated) to PAT this quarter — the dominant driver of the reported PAT jump. Consolidated JV/associate share swung to +₹5.96 Cr from -₹0.73 Cr YoY.